CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 59 enrolled
Drug / intervention
Colesevelam Hcldrug
Likely dose
Colesevelam Hcl 675 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01066364
NCT01066364Phase 2Completed
CompareCT.gov

Colesevelam Versus Placebo in the Treatment of Nonalcoholic Steatohepatitis

University of California, San Diego·interventional·Posted Feb 10, 2010·Updated Jul 21, 2020

In Brief

A Phase 2 clinical trial evaluating Colesevelam Hcl for Nonalcoholic Steatohepatitis. Completed, enrolled 59 participants across 2 sites.

Detailed Summary

The purpose of the study is to see if the drug colesevelam is a potential treatment for Nonalcoholic Steatohepatitis(NASH).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNonalcoholic Steatohepatitis
CountriesUnited States
CollaboratorsDaiichi Sankyo

Timeline

Phase 2CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedFeb 10, 2010
Enrollment StartFeb 1, 2010
Primary CompletionFeb 1, 2012
TodayJul 2, 2026
Enrollment to primary: 2 yearsPosted 16.4 years ago

Interventions

Colesevelam Hcldrug

3.75 gm/day (six 675 mg tablets)